Suggestions on the adjustment of therapeutic drugs for COPD in the national essential medicine list
- VernacularTitle:国家基本药物目录中COPD治疗药品的调整建议
- Author:
Licheng ZHANG
1
;
Ming GAO
1
;
Yufei FENG
2
;
Yanliang MA
3
;
Jiahua LENG
1
Author Information
1. Medical Insurance Service Division/Key Laboratory of Malignant Tumor Pathogenesis and Transformation Research Co-constructed by Ministry of Education，Beijing Cancer Hospital & Beijing Institute for Cancer Research，Beijing 100142，China
2. Dept. of Pharmacy，Peking University People’s Hospital，Beijing 100044，China
3. Dept. of Respiratory Medicine，Peking University People’s Hospital，Beijing 100044，China
- Publication Type:Journal Article
- Keywords:
chronic obstructive pulmonary disease
- From:
China Pharmacy
2023;34(16):1931-1935
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To provide a reference for the standardized treatment of chronic obstructive pulmonary disease （COPD） and the adjustment of therapeutic drugs for COPD in the national essential medicine list. METHODS Relevant clinical experts， pharmaceutical experts and medical insurance experts were invited to sort out the COPD treatment drugs involved in the domestic and foreign COPD clinical guidelines， the national essential medicine list， the WHO standard list of essential medicine， the national medical insurance catalogue， and comparatively analyzed the COPD treatment drugs. RESULTS & CONCLUSIONS Compared with domestic clinical guidelines， foreign clinical guidelines included an additional COPD triple preparation， while involving fewer types of expectorants and antioxidants； there were only 12 kinds of COPD treatment drugs included in the WHO standard list of essential medicine， while there were 18 kinds in the national essential medicine list in China， and more theophylline drugs， expectorants and antioxidants were included. In addition， 15 kinds of COPD treatment drugs were found in both the national clinical guidelines and the national medical insurance catalogue， but not in the national essential medicine list， including terbutaline， levalbuterol hydrochloride， salmeterol， formoterol， indacaterol， beclometasone， mometasone furoate， salbutamol ipratropium， glycopyrronium formoterol， umeclidinium vilanterol， indacaterol glycopyrronium， beclometasone formoterol， budesonide/glycopyrrolate/formoterol fumarate， fluticasone furoate/vilanterol/umeclidinium， and fudosteine， which were mainly long-acting beta 2-agonists and COPD triple preparations. These drugs had certain evidence-based medicine evidence， their efficacy and economy had certain advantages， and their impact on the budget of the medical insurance fund was controllable. Therefore， it is suggested that the aforementioned drugs should be included in the essential medicines list in the subsequent update.
